Investor Backing & Capital Strength:
Recent large funding rounds (an $80M Series C in April 2026 following a $45M Series B in 2024) and coverage noting a near-$1B valuation indicate strong investor support and ample capital to scale. Sequential financings across 2024–2026 signal continued access to growth funding.
Strong Market Position & Advantage:
Adoption by 16 of the top 20 MedTech companies and a customer count moving from 300+ to over 400 suggest deepening enterprise penetration. These signals align with a platform gaining prominence among leading industry players.
Innovation-Driven Growth:
Expansion from commercial intelligence into AI-enabled and agentic-AI workflows, along with new modules and integrations tied to the 2026 raise, reflects active product development. This broadening of capabilities supports wider use cases across sales, leadership, and marketing.
